## **Core Concept**
Abciximab is a medication used to prevent platelet aggregation during coronary interventions. It belongs to a class of drugs known as antiplatelet agents, specifically a monoclonal antibody that targets the glycoprotein IIb/IIIa receptor on platelets.

## **Why the Correct Answer is Right**
Abciximab works by binding to the glycoprotein IIb/IIIa receptor on platelets, which is the final common pathway for platelet aggregation. By blocking this receptor, abciximab effectively prevents fibrinogen from binding to platelets, thereby inhibiting platelet aggregation. This mechanism is crucial in the setting of percutaneous coronary interventions (PCI) to prevent thrombotic complications.

## **Why Each Wrong Option is Incorrect**
- **Option A:** This option is incorrect because abciximab is not a thrombolytic agent; it does not dissolve clots but rather prevents new clot formation.
- **Option B:** This option is incorrect as abciximab does not primarily work by inhibiting the coagulation cascade; it directly affects platelet function.
- **Option C:** This option might seem plausible but is incorrect because abciximab's action is more specific to preventing platelet aggregation rather than being broadly classified under anticoagulants, which can include a wide range of drugs affecting the coagulation cascade.

## **Clinical Pearl / High-Yield Fact**
A key point to remember is that abciximab is used in the setting of acute coronary syndromes, particularly during procedures like angioplasty and stenting to prevent platelet aggregation and stent thrombosis. Its use requires careful monitoring due to the increased risk of bleeding.

## **Correct Answer:** D. Glycoprotein IIb/IIIa inhibitor.